The Prevalence of Hepatitis B Virus, Hepatitis C Virus, and Human Immunodeficiency Virus Infections Among Hemodialysis Patients in Sulaimani City, Kurdistan, Iraq

Alaa Hussain  Al Krush; Mohamed Dler  Hama; Yousif Taha  Ghafoor; Las Omer  Rafiq

doi:10.56056/

Authors

Alaa Hussain Al Krush F.R.C. P, Assistant Professor of Medicine and Nephrology, Department of Medicine, College of Medicine, University of Sulaimani, Sulaimani, Iraq.
Mohamed Dler Hama Medical college student, University of Sulaimani, Sulaimani, Iraq.
Yousif Taha Ghafoor Medical college student, University of Sulaimani, Sulaimani, Iraq.
Las Omer Rafiq Medical college student, University of Sulaimani, Sulaimani, Iraq.

DOI:

https://doi.org/10.56056/

Keywords:

Hepatitis virus, Hemodialysis, Infection Control

Abstract

Background and objectives: Hemodialysis patients are more susceptible to Hepatitis B Virus, Hepatitis C Virus, and Human Immunodeficiency Virus infections due to contaminated medical equipment and frequent blood transfusions. The compromised immune systems of chronic renal patients further increase their vulnerability. The study aimed to determine the prevalence of Hepatitis B, C, and Human Immunodeficiency Virus infections among hemodialysis patients.

Methods: This observational study, conducted over two months in February 2024 in Qirga and Shar hemodialysis centers in Sulaimani city, surveyed 96 patients. Data on demographics, medical history, dialysis specifics, and Hepatitis B, C, and Human Immunodeficiency Virus markers were collected through interviews and blood tests.

Results: The findings indicate that Qirga Center has a higher prevalence of Hepatitis C Virus (10%) and Hepatitis B Virus (7%) infections than Shar Hospital (4.5% and 1.5%, respectively). Moreover, 6.3% of patients in both hospitals have Hepatitis C virus infection, compared to 3.1% of patients in both facilities who have Hepatitis B virus infection. All the results were statistically significant.

Conclusion: This study emphasizes the importance of vaccination, regular viral screening, and adherence to infection control protocols in hemodialysis units.

Downloads

Download data is not yet available.

References

1. Babanejad M, Izadi N, Najafi F, Alavian SM. The HBsAg Prevalence among blood donors from Eastern Mediterranean and Middle Eastern countries: a systematic review and meta-analysis. Hepat Mon. 2016 Mar; 16(3): e35664.

2. Mashragi F, Bernstein RS, Al-Mazroa M, Al-Tawfiq JA, Filemban S, Assiri A, et al. HIV transmission at a Saudi Arabia hemodialysis unit. Clin Infect Dis. 2014 Sep 15;59(6):897-902. doi: 10.1093/cid/ciu373. Epub 2014 May 20.

3. Fabrizi F, Messa P. Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015 Sep;38(9):471-80.

4. Fabrizi F, Dixit V, Messa P, Martin P. Transmission of hepatitis B virus in dialysis units: a systematic review of reports on outbreaks. Int J Artif Organs. 2015 Jan;38(1):1-7.

5. Cai G, Zheng H, Luo L, Wang Z, Jiang Z, Xu Set, al. Factors correlating to the development of hepatitis C virus infection in hemodialysis patients—findings mainly from Asiatic populations: a systematic review and meta-analysis. Int J Environ Res Public Health. 2019 Apr;16(8):1453.

6. Pesanti EL. Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am. 2001 Sep;15(3):813-32. doi: 10.1016/s0891-5520(05)70174-4/

7. Eleftheriadis T, Pissas G, Antoniadi G, Liakopoulos V, Stefanidis I. Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients. World J Gastroenterol. 2014 Sep 14; 20(34): 12018–12025.

8. Schillie S. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018;67(No. RR-1):1-31.

9. Lee CH, Hsieh SY, Chang CC, Wang IK, Huang WH, Weng CH, et al. Hepatocellular carcinoma in hemodialysis patients. Oncotarget. 2017 Sep 9;8(42):73154.

10. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality J Viral Hepat. 2012 Sep;19(9):601-7. doi: 10.1111/j.1365-2893.2012.01633. x. Epub 2012 Jul 17.

11. Ramzi ZS, Abdulla AA, Tariq AH, Al-Tawil NG. Prevalence and risk factors for hepatitis C virus infection in hemodialysis patients in Sulaimani. Zanco J Med Sci. 2010;14(1 Special):44-50.

12. Yakaryilmaz F, Alp Gurbuz O, Guliter S, Mert A, Songur Y, Karakan T, et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail. 2006;28(8):729-35. doi: 10.1080/08860220600925602/

13. Roth D, Fernandez JA, Burke GW, Esquenazi V, Miller J. Detection of antibody to hepatitis C virus in renal transplant recipients. Transplantation. 1991 Feb 1;51(2):396-400.

14. Jadoul M, Cornu C, de Strihou CV. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. Kidney Int. 1993 Dec;44(6):1322-6. doi: 10.1038/ki.1993.385/

15. Fabrizi F, Raffaele L, Bacchini G, Guarnori I, Pontoriero G, Erba G, et al. Antibodies to hepatitis C virus (HCV) and transaminase concentration in chronic haemodialysis patients: a study with second-generation assays. Nephrol Dial Transplant. 1993;8(8):744-7. doi: 10.1093/ndt/8.8.744/

16. Mittal G, Gupta P, Thakuria B, Mukhiya GK, Mittal M, et al. Profile of hepatitis B virus, hepatitis C virus, hepatitis d virus, and human immunodeficiency virus infections in hemodialysis patients of a tertiary care hospital in Uttarakhand. JCEH. 2013 Mar 1;3(1):24-8.

17. Shihab SS, Al-Hmudi HA, Al-Edani HS, Mahdi KH. Viral hepatitis infections in Basrah hemodialysis unit: serological diagnosis and viral loading. Eur J Exp Biol. 2014;4(2):106-2.

18. Fahmi N, Faruoq Z, Hassan WF, Ahmed A. Prevalence of viral hepatitis (B and C) in pediatric hemodialysis centers in Baghdad. IPMJ. 2018 Dec 28;17(4).

19. Al Shukri I, Al Wahaibi A, Al Kindi H, Al-Maimani Y, Al Maani A, Alqayoudhi A, et al. The Seroprevalence of Hepatitis C Virus (HCV) in Hemodialysis Patients in Oman: A National Cross-Sectional Study. J Epidemiol Glob Hea. 2023 Dec;13(4):774-8.

20. Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S, et al. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology. 2003 Oct;8(5):256-60.

21. Altinawe J, Akkawi ME, Kharrat Helu N, Hassan Q, Nattouf AH. Seroprevalence and risk factors of HBV, HCV and HIV among hemodialysis patients: a multicenter cross-sectional study from Damascus Syria. BMC Infect Dis. 2024 Mar 6;24(1):289. doi: 10.1186/s12879-024-09177-4/

22. Kataruka M, Gupta S, Ramchandran R, Singh M, Dhiman RK, Gupta KL. Incidence and risk factors for hepatitis C virus and hepatitis B virus seroconversion in end-stage renal failure patients on maintenance hemodialysis. J Clin Exp Hepatol. 2020 Jul 1;10(4):316-21.